The aim of the present analysis was to evaluate the efficacy of the glucagon‐like peptide‐1 receptor agonist liraglutide in Latino/Hispanic individuals with type 2 diabetes, in addition to comparing its treatment effects with those observed in non‐Latino/Hispanic individuals. Analyses were performed on patient‐level data from a subset of individuals self‐defined as Latino/Hispanic from four phase III studies, the LEAD‐3, LEAD‐4, LEAD‐6 and 1860‐LIRA‐DPP‐4 trials. Endpoints included change in glycated haemoglobin (HbA1c) and body weight from baseline. In Latino/Hispanic patients (n = 505; 323 treated with liraglutide) after 26 weeks, mean HbA1c reductions were significantly greater with both liraglutide 1.2 and 1.8 mg versus comparator or placebo in the LEAD‐3 and LEAD‐4 studies, and with 1.8 mg liraglutide in the 1860‐LIRA‐DPP‐4 trial. In LEAD‐3 both doses led to significant differences in body weight change among Latino/Hispanic patients versus the comparator. With 1.8 mg liraglutide, difference in weight change was significant only in the 1860‐LIRA‐DPP‐4 trial versus sitagliptin. For both endpoints Latino/Hispanic and non‐Latino/Hispanic patients responded to liraglutide similarly. In summary, liraglutide is efficacious for treatment of type 2 diabetes in Latino/Hispanic patients, with a similar efficacy to that seen in non‐Latino/Hispanic patients.